Panbela Therapeutics and Johns Hopkins to expand ivospemin development
Pharmaceutical Technology
APRIL 4, 2023
Ivospemin is a subcutaneously administered polyamine analogue being developed by Panbela to induce polyamine metabolic inhibition (PMI) through the exploitation of an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumours.
Let's personalize your content